Paradigm Biopharmaceuticals(AU:PAR)
A$0.250.00 (0.00%)
AU:PAR
Paradigm Biopharmaceuticals financials statements
A$0.25
At close:0.00 (0.00%)
Want to see AU:PAR full AI Analyst Report?
Paradigm Biopharmaceuticals (PAR) Ratios
46 Followers
Paradigm Biopharmaceuticals Ratios
AU:PAR's free cash flow for Q4 2026 was AU$0.00. For the 2026 fiscal year, AU:PAR's free cash flow was increased by AU$24.04M and operating cash flow was AU$-24.04M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.10 | 7.46 | 7.22 | 4.89 | 6.02 |
| Quick Ratio | 1.10 | 7.46 | 7.22 | 4.89 | 6.02 |
| Cash Ratio | 0.58 | 5.20 | 5.30 | 4.32 | 5.07 |
| Solvency Ratio | -2.07 | -5.53 | -16.32 | -3.86 | -4.66 |
| Operating Cash Flow Ratio | -1.64 | -4.95 | -19.63 | -3.46 | -4.11 |
| Short-Term Operating Cash Flow Coverage | -6.11 | 0.00 | -541.23 | -430.46 | -217.96 |
| Net Current Asset Value | AU$ 2.07M | AU$ 20.74M | AU$ 20.67M | AU$ 50.39M | AU$ 38.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.25 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 2.16 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.68 | 0.00 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 8.80 | 1.16 | 1.15 | 1.25 | 1.20 |
| Debt Service Coverage Ratio | -5.55 | -2642.23 | -429.99 | -428.55 | -221.41 |
| Interest Coverage Ratio | -24.83 | -3231.60 | -4536.74 | -3607.21 | -1641.85 |
| Debt to Market Cap | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.13 | 0.67 | 0.27 | 0.95 | 0.83 |
| Profitability Margins | |||||
| Gross Profit Margin | -102.76% | -38.17% | 86.34% | -40.26% | -81.45% |
| EBIT Margin | -76246.47% | -48535.61% | -98306.99% | -126039.35% | -59305.26% |
| EBITDA Margin | -76058.84% | -48436.95% | -98083.59% | -126308.81% | -59094.47% |
| Operating Profit Margin | -76246.47% | -43910.60% | -99077.51% | -126638.15% | -59339.34% |
| Pretax Profit Margin | -79790.11% | -48549.19% | -89138.30% | -126073.57% | -59340.60% |
| Net Profit Margin | -70282.28% | -36014.48% | -89138.30% | -111013.69% | -49543.07% |
| Continuous Operations Profit Margin | -70282.28% | -36014.48% | -89138.30% | -111013.69% | -49543.07% |
| Net Income Per EBT | 88.08% | 74.18% | 100.00% | 88.05% | 83.49% |
| EBT Per EBIT | 104.65% | 110.56% | 89.97% | 99.55% | 100.00% |
| Return on Assets (ROA) | -184.36% | -76.39% | -214.14% | -77.40% | -77.43% |
| Return on Equity (ROE) | -1623.03% | -88.61% | -246.38% | -96.71% | -92.76% |
| Return on Capital Employed (ROCE) | -1538.54% | -107.25% | -271.29% | -109.60% | -109.69% |
| Return on Invested Capital (ROIC) | -484.07% | -79.54% | -241.23% | -96.14% | -90.95% |
| Return on Tangible Assets | -189.99% | -77.70% | -239.96% | -80.95% | -82.21% |
| Earnings Yield | -92.26% | -19.57% | -68.96% | -18.61% | -17.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payables Turnover | 0.01 | 0.03 | 0.00 | 0.00 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.16 | 1.75 | 0.35 | 0.14 | 0.14 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 20965.54 | 30774.44 | -86373.12 | -182632.90 | 12956.84 |
| Days of Sales Outstanding | 59489.63 | 44636.36 | 28193.23 | 53136.55 | 30954.78 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 38524.09 | 13861.92 | 114566.34 | 235769.45 | 17997.94 |
| Operating Cycle | 59489.63 | 44636.36 | 28193.23 | 53136.55 | 30954.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.12 | -0.05 | -0.22 | -0.16 | -0.13 |
| Free Cash Flow Per Share | -0.12 | -0.05 | -0.22 | -0.16 | -0.13 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -3198643.00 | -1.00 | 0.00 | -8051316.50 |
| Capital Expenditure Coverage Ratio | 0.00 | -3198643.00 | -1.00 | 0.00 | -8051316.50 |
| Operating Cash Flow Coverage Ratio | -5.82 | -2916.34 | -275.54 | -132.25 | -52.22 |
| Operating Cash Flow to Sales Ratio | -545.06 | -306.85 | -1002.20 | -966.34 | -406.51 |
| Free Cash Flow Yield | -71.55% | -16.67% | -77.53% | -16.20% | -14.34% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.10 | -5.11 | -1.45 | -5.37 | -5.72 |
| Price-to-Sales (P/S) Ratio | 761.77 | 1840.42 | 1292.59 | 5965.35 | 2834.21 |
| Price-to-Book (P/B) Ratio | 17.59 | 4.53 | 3.57 | 5.20 | 5.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.40 | -6.00 | -1.29 | -6.17 | -6.97 |
| Price-to-Operating Cash Flow Ratio | -1.40 | -6.00 | -1.29 | -6.17 | -6.97 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.07 | -0.13 | -0.43 | 0.00 |
| Enterprise Value Multiple | -0.87 | -3.13 | -1.05 | -3.77 | -3.96 |
| Enterprise Value | 53.19M | 79.11M | 67.47M | 222.95M | 185.48M |
| EV to EBITDA | -0.87 | -3.13 | -1.05 | -3.77 | -3.96 |
| EV to Sales | 663.66 | 1517.85 | 1025.39 | 4767.93 | 2341.21 |
| EV to Free Cash Flow | -1.22 | -4.95 | -1.02 | -4.93 | -5.76 |
| EV to Operating Cash Flow | -1.22 | -4.95 | -1.02 | -4.93 | -5.76 |
| Tangible Book Value Per Share | 0.01 | 0.07 | 0.07 | 0.18 | 0.16 |
| Shareholders’ Equity Per Share | 0.01 | 0.07 | 0.08 | 0.19 | 0.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | 0.26 | 0.10 | 0.12 | 0.17 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.15 | -0.06 | -0.20 | -0.18 | -0.16 |
| Tax Burden | 0.88 | 0.74 | 1.00 | 0.88 | 0.83 |
| Interest Burden | 1.05 | 1.00 | 0.91 | 1.00 | 1.00 |
| Research & Development to Revenue | 672.69 | 340.39 | 886.53 | 1126.58 | 492.43 |
| SG&A to Revenue | 88.74 | 98.33 | 94.47 | 140.39 | 100.15 |
| Stock-Based Compensation to Revenue | 0.00 | 1.94 | 0.00 | 20.03 | 41.28 |
| Income Quality | 0.78 | 0.85 | 1.12 | 0.87 | 0.82 |
Currency in AUD
